A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer

LESSONS LEARNED. The combination of standard dose abiraterone acetate and BEZ235, a pan‐class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC. Although the clinical development of BEZ235 has been discontinued in prostate cancer, agents that more selectively target P...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiao X., Hsieh, Andrew C., Kim, Won, Friedlander, Terence, Lin, Amy M., Louttit, Mirela, Ryan, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423513/
https://www.ncbi.nlm.nih.gov/pubmed/28314838
http://dx.doi.org/10.1634/theoncologist.2016-0432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423513/
https://www.ncbi.nlm.nih.gov/pubmed/28314838
http://dx.doi.org/10.1634/theoncologist.2016-0432

Ejemplares similares